Blog Archives

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),

Read more ›

Tags: , , , , , , ,

Living theragenomic medicine: Direct to consumer test for metabolism of drugs FDA approved

November 08, 2018 –  The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients.

Thus, FDA permits marketing, with special controls,

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Parkinsons Disease: Positive opinion by the CHMP issued recommending the granting of a marketing authorisation for Safinamide (Xadago)

On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xadago, 50 mg and 100 mg, film-coated tablet intended for the treatment of Parkinson’s disease. 

Read more ›

Tags: , , , ,

Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.  

The American Food &

Read more ›

Tags: , , , , , , ,

X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue

 December 16, 2017 – As recent as of December 14, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Burosumab (Crysvita),

Read more ›

Tags: , , , , , , , ,

Besponsa: Is this really a viable new treatment for ALL?

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, the National Cancer Institute estimates that approximately 5,970 people will be diagnosed with B-cell ALL this year and approximately 1,440 will die from the disease.

Read more ›

Tags: , , , , , , , , , , ,

Rare diseases: EU and US collaborate to boost development of therapies

September 30, 2016 – This is very good news for patients suffering from any form of a rare disease. The European Medicines Agency (EMA) and the American Food and Drug Administration (FDA) have engaged in a joint effort to boost development of medicines for rare diseases.

Read more ›

Tags: , , , , ,

Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 deaths from the disease. Hormone receptor positive breast cancer accounts for 65% of tumours in women aged 35 to 65 years and 82% of tumours in women older than 65 years.

Read more ›

Tags: , , , , , , , , , , , , ,

Patient safety: EMA recommends suspension of medicines over flawed studies

August 08, 2016 –The following publication has just been released by the EMA. Because Thasso Post is not only about theragenomic and personalized medicine, but also about the safety of medicines for each individual patient, thasso feels that this is important information which highlights the degree of scrutiny applied by authorities in the quest to guarantee the quality and safety of approved medicines.

Read more ›

Tags: , , , ,

With Infliximab (Flixabi), a huge biosimilar medicine has been approved in the European Union (EU)

 June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block its activity.

Read more ›

Tags: , , , , , , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genomic adaptations to a rice-based diet mitigate the risk of obesity and diabetes September 21, 2020
    The traditional rice-based diet of some east-Asian population has brought a number of genomic adaptations that may contribute to mitigating the spread of diabetes and obesity. An international study led by the University of Bologna and published in the journal Evolutionary Applications has recently suggested this interesting hypothesis. Researchers analyzed and compared the genomes of […]
  • Researchers identify genetic factors associated with hand-foot syndrome in chemotherapy with capecitabine September 21, 2020
    Capecitabine is a chemotherapy drug used for breast and colorectal cancer. It can extend survival rate by nearly 10%. However, recent studies revealed that almost 50% of patients develop palmar-plantar erythrodysesthesia, a skin reaction also called hand-foot syndrome with mild to serious symptoms. Up to 17% of these patients can have a burning pain in […]
  • Gene therapy corrects the cardiac effects of Friedreich's ataxia September 18, 2020
    Gene therapy was successfully used to overcome the cardiac effects of Freidreich's ataxia (FA) in a mouse model of the disease, as reported in the peer-reviewed journal Human Gene Therapy.
  • Algorithms uncover cancers' hidden genetic losses and gains September 17, 2020
    Understanding the specific mutations that contribute to different forms of cancer is critical to improving diagnosis and treatment. But limitations in DNA sequencing technology make it difficult to detect some major mutations often linked to cancer, such as the loss or duplication of parts of chromosomes.
  • Researcher finds keys to control the 'driver of cancer's aggressiveness' September 17, 2020
    'Do not erase.' 'Recycle me.' 'Free to a good home.' Humans post these signs to indicate whether something has value or not, whether it should be disposed of or not. Inside our cells, a sophisticated recycling system uses its own enzymatic signs to flag certain cells for destruction—and a different set of enzymes can remove […]
  • Awareness of COVID-19 in severe dementia patients September 21, 2020
    Tokyo, September 21, 2020- The ongoing coronavirus disease 2019 (COVID-19) pandemic has substantially affected patients with dementia and their caregivers.
  • Cleveland Clinic study finds no link between influenza vaccine and COVID-19 risk September 21, 2020
    Using patient data from Cleveland Clinic's COVID-19 registry, Dr. Joe Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.
  • Bio-based inhibition of gas hydrate formation September 21, 2020
    Copper stearate was used as the basis for this catalyst test and showed efficiency for in-situ oil combustion.
  • Biodiversity hypothesis called into question September 21, 2020
    How can we explain the fact that no single species predominates? A generally accepted hypothesis is that a trade-off exists between organisms able to acquire and consume more food than other when resources are scarce, and organisms which rapidly consume large quantities of food when they are in abundance. However, when scientists from the University […]
  • A faster and more reliable method to categorize olive oil is validated September 21, 2020
    Classifying olive oils into the categories of extra virgin (EVOO), virgin (VOO) and lampante (LOO) is still quite a challenge to deal with since the official method includes physical-chemical and sensory analyses by means of a panel of tasters. These tasters need to be specialized, and on many occasions are not available, in addition to […]
Top